Literature DB >> 16183708

Induction of beta3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes.

Renée Germack1, John M Dickenson.   

Abstract

This study aimed to characterize beta(3)-adrenergic receptors (ARs) in rat neonatal cardiomyocytes using the noradrenaline (NOR) properties to modulate the expression and function of the three beta-ARs. We assessed the effect of NOR (physiological nonselective agonist), isoprenaline (ISO, beta-nonselective agonist), dobutamine (DOB, beta(1)-selective agonist), and procaterol (PROC, beta(2)-selective agonist) on cAMP accumulation using cardiomyocytes untreated or treated with 100 microM NOR for 24 h. The inhibition of forskolin-stimulated cAMP accumulation was determined using NOR, isoprenaline, and the beta(3)-selective agonists 4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic acid (BRL 37344) and 5-[-2-([-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243). The experiments were performed in the absence or presence of propranolol or 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP 20712A) and/or 1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride (ICI 118551) to inhibit beta(1)- and beta(2)-AR stimulation and 1-(2-ethylphenoxy)-3-[[1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino-(2S)-2-propanol hydrochloride (SR 59230A) (beta(3)-selective antagonist). In addition, the level of the three subtypes was determined by reverse transcription polymerase chain reaction and Western blotting. NOR pretreatment decreased the activation of cAMP induced by NOR, isoprenaline, and DOB, whereas PROC response was abolished. The inhibition of NOR response by CGP 20712A or ICI 118551 demonstrated that beta(1)- and beta(2)-ARs are down-regulated and that beta(2)-AR functional activity was also abolished in cardiomyocytes exposed to chronic stimulation. beta(3)-AR function was observed with NOR and ISO when beta(1)-/beta(2)-ARs were blocked and with both beta(3)-selective agonists in NOR-treated cells only. This response was completely inhibited by SR 59230A and involved G(i) protein. Furthermore, the results from functional studies agree well with those from expression experiments. In conclusion, these data provide strong evidence that beta(3)-ARs are functionally up-regulated and coupled to G(i) protein in rat neonatal cardiomyocytes following chronic exposure to NOR when beta(1)- and beta(2)-ARs are down-regulated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183708     DOI: 10.1124/jpet.105.090597

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

Review 1.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

Review 2.  Role of β-adrenergic receptors and nitric oxide signaling in exercise-mediated cardioprotection.

Authors:  John W Calvert; David J Lefer
Journal:  Physiology (Bethesda)       Date:  2013-07

Review 3.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

4.  Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase.

Authors:  Xiaolin Niu; Vabren L Watts; Oscar H Cingolani; Vidhya Sivakumaran; Jordan S Leyton-Mange; Carla L Ellis; Karen L Miller; Konrad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Nazareno Paolocci; David A Kass; Lili A Barouch
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

5.  Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling.

Authors:  Gizem Kayki Mutlu; Ebru Arioglu Inan; Irem Karaomerlioglu; V Melih Altan; Nilgun Yersal; Petek Korkusuz; Marcella Rocchetti; Antonio Zaza
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

Review 6.  Mirabegron: potential off target effects and uses beyond the bladder.

Authors:  Nodi Dehvari; Edilson Dantas da Silva Junior; Tore Bengtsson; Dana Sabine Hutchinson
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

7.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

8.  Cross-regulation between beta 1- and beta 3-adrenoceptors following chronic beta-adrenergic stimulation in neonatal rat cardiomyocytes.

Authors:  Christoph Ufer; Renée Germack
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

9.  Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes.

Authors:  Yi Xia; Kai-Zheng Gong; Ming Xu; You-Yi Zhang; Ji-Hong Guo; Yao Song; Ping Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

10.  Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2.

Authors:  Alessandra Scarpellini; Renée Germack; Hugues Lortat-Jacob; Takashi Muramatsu; Ellen Billett; Timothy Johnson; Elisabetta A M Verderio
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.